Advertisement
U.S. markets open in 31 minutes
  • S&P Futures

    5,306.00
    -2.25 (-0.04%)
     
  • Dow Futures

    40,170.00
    +26.00 (+0.06%)
     
  • Nasdaq Futures

    18,486.00
    -17.75 (-0.10%)
     
  • Russell 2000 Futures

    2,140.10
    +1.70 (+0.08%)
     
  • Crude Oil

    82.69
    +1.34 (+1.65%)
     
  • Gold

    2,229.00
    +16.30 (+0.74%)
     
  • Silver

    24.68
    -0.07 (-0.27%)
     
  • EUR/USD

    1.0808
    -0.0021 (-0.19%)
     
  • 10-Yr Bond

    4.2220
    +0.0260 (+0.62%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2641
    +0.0003 (+0.03%)
     
  • USD/JPY

    151.2040
    -0.0420 (-0.03%)
     
  • Bitcoin USD

    70,521.21
    +377.82 (+0.54%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,951.64
    +19.66 (+0.25%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit

Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc.

ISELIN, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will be presenting at the Wet AMD and DME Drug Development Summit taking place April 5-7, 2022 in Boston, Massachusetts.

Details for the presentation are as follows:

Session: Seeking Improved Therapeutics for Wet AMD & DME Patients
Title: Enhancing the Standard of Care in Wet AMD, BRVO, & DME
Presenter: Russ Trenary, President and CEO, Outlook Therapeutics
Date and Time: Wednesday, April 6, 2022, 9:45 AM EST

For more information, please visit wet-amd-drugdevelopment.com.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg), an investigational therapy, as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD. The submission is supported by Outlook Therapeutics’ wet AMD registration clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com


Advertisement